Arrowstreet Capital
ZVRA icon

Arrowstreet Capital’s Zevra Therapeutics ZVRA Stock Holding History

Arrowstreet Capital’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.56M Buy
+597,162
New +$6.64M ﹤0.01% 1132

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
RPCONE
Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Arrowstreet Capital's ZVRA Position: Q2 2026 in Review

Arrowstreet Capital opened a new position in Zevra Therapeutics (ZVRA) in Q2 2026: 597,162 shares worth $8.56M. The stake represents ﹤0.01% of the portfolio and ranks #1132 among its holdings.

106 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Arrowstreet Capital held 597,162 shares of Zevra Therapeutics worth $8.56M as of Q2 2026.
  • Zevra Therapeutics was a new Arrowstreet Capital position in Q2 2026.
  • Zevra Therapeutics made up ﹤0.01% of Arrowstreet Capital's portfolio in Q2 2026, its #1132 holding.
  • 106 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.